Inter- and intra-core laboratory variability in the quantitative coronary angiography analysis for drug-eluting stent treatment and follow up [0.03%]
药物洗脱支架治疗及随访的定量冠状动脉造影分析的室间和室内变异度研究
Shigenori Ito,Kanako Kinoshita,Akiko Endo et al.
Shigenori Ito et al.
Aim: To evaluate inter-core laboratory variability of quantitative coronary angiography (QCA) parameters in comparison with intra-core laboratory variability in a randomized controlled trial evaluating drug-eluting stents...
Randomized Controlled Trial
Therapeutic advances in cardiovascular disease. 2020 Jan-Dec:14:1753944720958982. DOI:10.1177/1753944720958982 2020
The atrial flow regulator: current overview on technique and first experience [0.03%]
房腔流量调节器：技术概览与初步体验
Christina Paitazoglou,Martin W Bergmann
Christina Paitazoglou
Safety of day-case endovascular interventions for peripheral arterial disease in a rural, underserved area [0.03%]
在农村、医疗资源不足的地区对周围动脉疾病进行日间介入治疗的安全性
Athar Ansari,Moiz Ali Shah,Manaim Amir Shah et al.
Athar Ansari et al.
Background: We aimed to investigate the safety of endovascular procedures undertaken in a single outpatient center located in a rural, underserved area. Endovascular procedures for Peripheral Arterial Disease (PAD) have b...
Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation [0.03%]
钠-葡萄糖共转运蛋白(SGLT)₂抑制剂可缓解导致交感神经激活的肾脏应激反应
Motoaki Sano
Motoaki Sano
This review focuses on the pathogenic role of sodium glucose cotransporter (SGLT)-2 in the development of renal dysfunction and heart failure in patients with diabetes, by emphasizing the concept of reno-cardiac syndrome (kidney injury wors...
Flecainide is well-tolerated and effective in patient with atrial fibrillation at 12 months: a retrospective study [0.03%]
氟卡尼治疗心房颤动患者疗效及安全性回顾性研究
Mikayla Muzzey,Katie B Tellor,Karthik Ramaswamy et al.
Mikayla Muzzey et al.
Introduction: Current atrial fibrillation (AF) guidelines recommend flecainide as a first-line rhythm control option in patients without structural heart disease. While there is proven efficacy in clinical trials and guid...
Lucia Dallapellegrina,Edoardo Sciatti,Enrico Vizzardi
Lucia Dallapellegrina
Ivabradine is a pure heart-rate lowering drug that is nowadays used, accordingly to the last ESC Guidelines, to reduce mortality and heart failure (HF) hospitalization in patients with HF with reduced ejection fraction and in symptomatic pa...
Gani Nuredini,Alec Saunders,Chakravarthi Rajkumar et al.
Gani Nuredini et al.
White coat hypertension (WCH) is characterised by an elevated clinic blood pressure (BP) with normal ambulatory or home BP. It is well recognised in clinical practice and occurs in approximately one-third of untreated patients with elevated...
Exercise therapy in routine management of peripheral arterial disease and intermittent claudication: a scoping review [0.03%]
外周动脉疾病和间歇性跛行常规管理中的运动疗法：系统综述
Ukachukwu O Abaraogu,Onyinyechukwu D Abaraogu,Philippa M Dall et al.
Ukachukwu O Abaraogu et al.
Background: Little is known about the extent to which routine care management of peripheral arterial disease (PAD) and intermittent claudication (IC) align with best practice recommendations on exercise therapy. We conduc...
Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven®) utilization at a large academic medical center [0.03%]
关于重组活化因子VII在大型医学中心使用的效果和不良事件的药物管理研究
Kassandra Marsh,David Green,Veronica Raco et al.
Kassandra Marsh et al.
Background: Recombinant factor VIIa (rFVIIa) (Novoseven®) is utilized for the reversal of anticoagulation-associated bleeding and refractory bleeding in cardiac surgery. In August 2015, rFVIIa was transferred from the bl...